PPBT vs PPCB

Purple Biotech Ltd. vs Propanc Biopharma, Inc. — Valuation Comparison 2026

PPBT

Biotechnology
Purple Biotech Ltd.
Quality
3.6
out of 10
Value Trap
Price
$2.81
Last close
Models
2/13
Active
VS

PPCB

Biotechnology
Propanc Biopharma, Inc.
Quality
3.7
out of 10
Value Trap
36
LOW
Price
$1.70
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType PPBT Fair ValuePPBT Upside PPCB Fair ValuePPCB Upside
Bayesian DCF Intrinsic $0.50 -70.8%
EROIC Spread Intrinsic $1.34 -52.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.54 -80.7%
Dynamic NAV Asset-Based $6.64 +290.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PPBT vs PPCB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PPBT vs PPCB — Which Stock Is More Undervalued?

PPCB scores higher with a 3.7/10 quality rating vs PPBT's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Purple Biotech Ltd. (PPBT) and Propanc Biopharma, Inc. (PPCB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PPBT currently trades at $2.81 with a QOC of 3.6/10, while PPCB trades at $1.70 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).